Renalytix AI Launches Trial To Identify COVID-19 Patients With Kidney Injury
The Mount Sinai spin-off believes its KindeyIntelX system can identify COVID-19 patients at high risk for long-term kidney damage.
You may also be interested in...
JPM 2021: Intuitive Surgical, Accelerate Diagnostics, Siemens Healthineers, Exact Sciences, Renalytix
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the third day of the meeting.
The company is planning to produce up to 10 million COVID-SeroKlir SARS-CoV-2 IgG antibody test kits a month through a partnership with Bio-Techne.
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.